In an update from Jamaica’s health authorities, Chief Medical Officer Dr. Jacquiline Bisasor-McKenzie has confirmed the discontinuation of the AstraZeneca COVID-19 vaccine as of July 2022.
This decision aligns with a global withdrawal application that took effect on May 7, following admissions by the vaccine’s manufacturer about the potential, albeit rare, risk of blood clots.
Public health reassurances
During a post-Cabinet press briefing, Dr. Bisasor-McKenzie addressed public concerns, clarifying that the vaccine had ceased to be available on the market due to the expiration of the country’s last vaccine doses in July 2022.
She reassured the public that the risk of side effects associated with the vaccine typically occurs within three months of administration, confirming that those vaccinated in 2021 or early 2022 are no longer at risk.
Monitoring and investigating side effects
The Ministry of Health and Wellness remains vigilant, continuing to gather and investigate reports of possible vaccine-related side effects.
Dr. Bisasor-McKenzie emphasized the rarity of the noted side effect, occurring in approximately two out of every 100,000 vaccinated individuals.
Ongoing surveillance and prevention
Highlighting the comprehensive process of drug approval and monitoring, the Chief Medical Officer pointed out that post-market surveillance is a critical component of ensuring drug safety after clinical trials.
Meanwhile, Jamaica continues its COVID-19 vaccination efforts, adhering to World Health Organization guidelines on booster shots to ensure public health safety.
